Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial.
The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.
The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
Company Details
- Employees
- 59
- Founded
- -
- Address
- Boston, Massachusetts, Us
- Phone
- +972-77-5558482
- in****@****nia.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- prilenia.com
- HQ
- Boston, Massachusetts
Prilenia Questions
Prilenia's helpline number is +972-77-5558482
Prilenia's website is prilenia.com
Prilenia's LinkedIn profile is https://www.linkedin.com/company/prilenia
Prilenia has
59 employees.
View email and phone details for 59
employees at Prilenia.
Prilenia's industry is
Biotechnology Research
Prilenia's top competitors are
Clexio Biosciences,
Ionis Pharmaceuticals, Inc.,
Argenx,
Clene Nanomedicine, Inc.,
Dyne Therapeutics,
Brainstorm Cell Therapeutics,
Neurosense Therapeutics,
Ferrer,
1e Therapeutics,
Wave Life Sciences.
Prilenia's support email address is info@prilenia.com
Prilenia's categories are Biotechnology Research
Prilenia's founding year is 2018
